Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Laura Cisar"'
Publikováno v:
Journal of Oncology Pharmacy Practice. 24:574-583
Purpose The purpose is to describe management of adverse events of special interest across tyrosine kinase inhibitors approved for metastatic renal cell carcinoma. Methods We conducted a retrospective chart review in metastatic renal cell carcinoma p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98205526a8f619976582dd51ee9d838f
https://doi.org/10.1177/1078155217719583
https://doi.org/10.1177/1078155217719583
Autor:
Jamal Tarazi, Subramanian Hariharan, Thomas E. Hutson, M. Dror Michaelson, Laura Cisar, Angel H. Bair, Yoshihiko Tomita, Brad Rosbrook, Mayer Fishman, Brian I. Rini, Eric Jonasch, Victor Gruenwald
Publikováno v:
Targeted Oncology. 12:333-340
We conducted a retrospective analysis of two clinical trials in treatment-naïve patients (n = 402) with advanced renal cell carcinoma (RCC) treated with axitinib. Our objective was to compare duration of treatment (DT) and clinical outcome in patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dfec3d3e870ef7863c5306532a0fb690
https://doi.org/10.1007/s11523-017-0487-4
https://doi.org/10.1007/s11523-017-0487-4
Publikováno v:
Future oncology (London, England). 13(15)
Aim: To study patient characteristics and treatment patterns in real-world axitinib use for metastatic renal cell carcinoma. Patients & methods: We conducted a retrospective analysis of second- or third-line axitinib use between 1 January 2012 and 31
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bdd41f270787a9b095cf5187d23de6b6
https://pubmed.ncbi.nlm.nih.gov/28485672
https://pubmed.ncbi.nlm.nih.gov/28485672
Autor:
Robert J. Motzer, Michael S. Baum, Jamal Tarazi, Laura Cisar, W. Gregory Roberts, Lillian Shahied Arruda, Sinil Kim, David I. Quinn, Laura S. Wood, Brian I. Rini, Brad Rosbrook
Publikováno v:
Targeted Oncology
Inhibitors of the vascular endothelial growth factor (VEGF) pathway frequently induce hypertension when used to treat patients with advanced renal cell carcinoma (RCC). This analysis characterizes hypertension and hypertension-related events in patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f3e411bfc3816d9d15b635d9e165217
http://europepmc.org/articles/PMC4363524
http://europepmc.org/articles/PMC4363524
Publikováno v:
Journal of managed carespecialty pharmacy. 22(8)
Sunitinib and pazopanib are among the most prescribed targeted therapies for the systemic management of advanced renal cell carcinoma (RCC), but published cost comparisons between the 2 agents are few and limited by methodological and population diff
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e925a6ee06ff7d137f77f512e126f16b
https://pubmed.ncbi.nlm.nih.gov/27459661
https://pubmed.ncbi.nlm.nih.gov/27459661
Publikováno v:
Journal of managed carespecialty pharmacy. 22(6)
Axitinib is approved by the FDA for the treatment of advanced renal cell carcinoma (RCC) after failure of 1 previous systemic therapy and is distributed primarily through specialty pharmacies. Although the efficacy and safety of axitinib have been es
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b2e280d4e4acb93c90e63740368e5ce
https://pubmed.ncbi.nlm.nih.gov/27231799
https://pubmed.ncbi.nlm.nih.gov/27231799
Publikováno v:
Archives of Drug Information. 1:97-106
Purpose. Statistical models for predicting hematologic toxicity were evaluated based on UGT1A1 polymorphisms and baseline serum bilirubin. Methods. Blood DNA samples were collected from 113 patients with untreated metastatic colorectal cancer receivi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ffb405e7ebb37e11286a658b3a84f7ec
https://doi.org/10.1111/j.1753-5174.2008.00014.x
https://doi.org/10.1111/j.1753-5174.2008.00014.x
Autor:
Daniel Orbach, Christophe Bergeron, Jean Claude Gentet, Gilles Vassal, Susan Picton, Birgit Geoerger, Anne Geoffray, Bruce Morland, Elizabeth Stockdale, Dominique Couanet, Sylvie Assadourian, Fabienne Pichon, Laura Cisar
Publikováno v:
Journal of Clinical Oncology. 25:356-361
Purpose This phase II study was designed to evaluate the efficacy of irinotecan administered intravenously once every 3 weeks in pediatric patients with recurrent or refractory rhabdomyosarcoma. Patients and Methods A total of 35 patients younger tha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7cafec4ae470ebd83e10e6be5e2a370
https://doi.org/10.1200/jco.2006.06.1960
https://doi.org/10.1200/jco.2006.06.1960
Autor:
Richard M. Goldberg, Gabriela Gruia, Gary Elfring, Mace L. Rothenberg, Rakesh Goel, Donghua Yin, Larry J. Schaaf, Lisa A. Hammond, Stuart J. Tipping, Barbara A. Duncan, Linda D. Compton, J. Patrick McGovren, Langdon L. Miller, Amarnath Sharma, John G. Kuhn, Nicoletta Pirotta, Laura Cisar
Publikováno v:
Clinical Cancer Research. 12:3782-3791
Purpose: To determine the recommended starting doses and pharmacokinetics of irinotecan in cancer patients with impaired liver function treated on a weekly schedule. Experimental Design: Patients with solid tumors who had impaired liver function were
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8896bbf5fbfd55ba221b8fbf37c9370b
https://doi.org/10.1158/1078-0432.ccr-05-2152
https://doi.org/10.1158/1078-0432.ccr-05-2152
Autor:
Laura Cisar, Nicoletta Orlando, Mark R. Green, Wilson H. Miller, Langdon L. Miller, Caio Max S. Rocha Lima, Adele Morganti, Gabriela Gruia, G. Mark Jeffrey, Robert Rotche
Publikováno v:
Journal of Clinical Oncology. 22:3776-3783
Purpose This phase III, randomized, open-label, multicenter study compared the overall survival associated with irinotecan plus gemcitabine (IRINOGEM) versus gemcitabine monotherapy (GEM) in patients with chemotherapy-naive, locally advanced or metas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8083a6376626b2ddd16402c911d0fc40
https://doi.org/10.1200/jco.2004.12.082
https://doi.org/10.1200/jco.2004.12.082